The Worldwide Innovative Networking (WIN) Consortium in personalized cancer medicine was initiated in 2010 with leadership from leading cancer centers worldwide. WIN is a non-profit, non-governmental organization headquartered in Paris.

WIN was created to accelerate the pace and reduce the cost of translating novel cancer treatments to the bedside by developing and applying, through worldwide clinical trials and research projects, the most promising advances in genomic-based cancer research. WIN aims to initiate research projects each year in a global consortium guided by an independent scientific advisory board.

WIN now includes 35 institutional members. These stakeholders have come together from all parts of the world to address the challenge of increasing the efficacy of cancer diagnostics and therapeutics by understanding the genetics and biology of each individual’s tumor and accounting for genetic differences across diverse populations—from North and South America, Europe, Asia, and the Middle East.

Our goal is to significantly improve outcomes for patients around the globe. We aim to increase the number of patients worldwide that have access to innovative, global clinical trials in the area of genomic-based cancer therapeutics. Global diversity and inclusion of all stakeholders is WIN’s most important and differentiating asset.

WIN enables cross-sector collaborations designed to accelerate the speed and efficacy with which breakthroughs in personalized cancer medicine can be realized and brought to patients worldwide.

Our members include leading academic, pharmaceutical, life science, not-for-profit, health, patient advocacy and IT organizations.

The response to a genetically-targeted therapy can vary due to differences in ethnicity and environment. WIN's global studies are designed to identify and account for this variability, enhancing the speed and efficacy with which novel discoveries can be made and brought to patients around the world.

WIN Symposia, held annually, brings together hundreds of leaders representing all stakeholders from around the world in a forum designed to promote the exchange of ideas and information.

WIN's article “Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival” published by NPJ Precision Oncology, a Nature Research journal.

The WIN SPRING trial was conducted in the USA, France, Spain, Luxembourg and Israel in the following cancer centers: University of California - San Diego's Moores Cancer Center, Avera Cancer Center (Sioux Falls, Arizona), Institut Curie (Paris), Centre Léon Bérard (Lyon), Vall d'Hebron Institute of Oncology (Barcelona), Centre Hospitalier de Luxembourg (Luxembourg), and Chaim Sheba Medical Center (Israel).

The trial was sponsored by the WIN Consortium and funded by ARC Fondation for cancer research (France). The drugs were donated by Pfizer Inc.

Published in Nature Medicine, results of WINTHER, the first study pioneered by the WIN Consortium.

Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial - shows that RNA profiling together with DNA testing matches more patients with advanced cancer to personalized therapies than DNA profiling for tumor mutations alone.

European funded trials WINTHER EU FP7 funded and CHEMORES EU FP6 funded established foundations for WIN future global strategy for lung cancer currently under development.

The concept underlying the new strategy is developed in the following publications:

Jun 02, 2022 | Adam Bonislawski
NEW YORK – (GenomeWeb)

Backed by data from a 200-person clinical study, glycoproteomics firm InterVenn Biosciences has released its first commercial product, a mass spectrometry-based test for guiding immunotherapy in melanoma patients.

Called Dawn IO Melanoma, the test is intended to determine whether advanced melanoma patients are likely or unlikely to respond to treatment with immune checkpoint inhibitors, specifically either Merck's Keytruda (pembrolizumab) alone or Bristol-Myers Squibb's Yervoy (ipilimumab) in combination with BMS's Opdivo (nivolumab).

InterVenn also announced this week that it has joined the Worldwide Innovative Network (WIN) Consortium and the Foundation for the National Institutes of Health’s Biomarker Consortium and will bring its glycoproteomic-focused approach to biomarker discovery to both organizations.

Read the full article here:
Download pdf

Cancer Medicine, Wiley
March 20, 2022

Abstract
Background: The Worldwide Innovative Network (WIN) Consortium has developed the Simplified Interventional Mapping System (SIMS) to better define the cancer molecular milieu based on genomics/transcriptomics from tumor and analogous normal tissue biopsies. SPRING is the first trial to assess a SIMS-based tri-therapy regimen in advanced non-small cell lung cancer (NSCLC).

Cancer Med.
2022;00:1–11. doi: 10.1002/cam4.4635

View the full article: Download pdf

January 4, 2022 - The Journal of Immunotherapy and Precision Oncology (jipoonline.og) and WIN Consortium (winconsortium.org) are proud to announce a strategic partnership for 2022.

Aung Naing, MD, Editor-in-Chief of JIPO says, "We at JIPO are excited about our collaboration with WIN. Our shared vision is to advance clinical practice of immunotherapy and precision oncology that transforms patient care. JIPO is a peer-reviewed, open access journal with a fair and efficient double-blinded review process. Our mission is to disseminate accurate scientific knowledge, including both positive and negative studies, related to translational science and clinical medicine.” Naing further elaborates, "Our editorial board comprises renowned physicians and physician-scientists from diverse backgrounds and from different parts of the world. Our collaboration with WIN will enable us to realize our shared vision."

Razelle Kurzrock, MD, Chief Medical Officer of WIN says, “JIPO is positioned to have a high impact on the entire field of immunotherapy and precision oncology. The Worldwide Innovative Network (WIN) for precision medicine has goals well aligned with JIPO, considering its track record, including a multinational precision medicine that was the first to include transcriptomics as well as genomics in order to successfully match cancer patients with drugs. We are proud to partner with JIPO to help bring the latest knowledge about innovative therapies to patients suffering from malignancies."

JIPO and WIN will cross-promote both organization’s activities throughout the year, including the WIN 2022 Symposium in Barcelona, Spain, March 14-15, 2022. Abstracts selected for presentation at the WIN meeting will be published in JIPO as a Conference Proceeding.

JIPO Editorial Fellow, Dr. Khalid Jazieh, will be interviewing members of WIN Leadership to highlight the collaboration and upcoming activities. Drs. Razelle Kurzrock, Vladimir Lazar, and Richard L. Schilsky will be interviewed. These interviews will be published on the JIPO YouTube channel in the coming weeks.

Dr. Vladimir Lazar, Chief Scientific and Operating Officer of WIN, has been appointed to the JIPO Editorial Board to represent WIN Leadership. Dr. Lazar plans to contribute an editorial to the Journal in 2022. Dr. Kurzrock has published four articles in JIPO in 2019 and 2020.

Download pdf

NPJ Precision Oncology, a Nature Research journal
Apr 28, 2021

Abstract
The expanding targeted therapy landscape requires combinatorial biomarkers for patient stratification and treatment selection. This requires simultaneous exploration of multiple genes of relevant networks to account for the complexity of mechanisms that govern drug sensitivity and predict clinical outcomes. We present the algorithm, Digital Display Precision Predictor (DDPP), aiming to identify transcriptomic predictors of treatment outcome. For example, 17 and 13 key genes were derived from the literature by their association with MTOR and angiogenesis pathways, respectively, and their expression in tumor versus normal tissues was associated with the progression-free survival (PFS) of patients treated with everolimus or axitinib (respectively) using DDPP. A specific eight-gene set best correlated with PFS in six patients treated with everolimus: AKT2, TSC1, FKB-12, TSC2, RPTOR, RHEB, PIK3CA, and PIK3CB (r = 0.99, p = 5.67E−05). A two-gene set best correlated with PFS in five patients treated with axitinib: KIT and KITLG (r = 0.99, p = 4.68E−04). Leave-one-out experiments demonstrated significant concordance between observed and DDPP predicted PFS (r = 0.9, p = 0.015) for patients treated with everolimus. Notwithstanding the small cohort and pending further prospective validation, the prototype of DDPP offers the potential to transform patients’ treatment selection with a tumor- and treatment-agnostic predictor of outcomes (duration of PFS).

npj Precision Oncology (2021)5:33;
https://doi.org/10.1038/s41698-021-00171-6

Download the full article here: Download pdf

===============================================
WIN Press Release
VILLEJUIF, FRANCE, April 30, 2021
EINPresswire.com

The Worldwide Innovative Network in personalized cancer medicine consortium - WIN Consortium announces the publication of the Digital Display Precision Predictor: the
prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival for cancer patients in NPJ Precision Oncology (10.1038/s41698- 021-00171-6).

Precision oncology has led to approved, molecularly specific, biomarker-defined indications for targeted therapies. With the number of validated drug targets increasing, testing each patient’s tumor for all markers related to all possible targeted therapies becomes infeasible due to limited amount of tissue usually obtained by biopsies. In addition, the current companion diagnostic
approach used for most targeted therapies provides limited treatment options, with a binary "yes/no" expected response to a drug and no recommendation for which treatment, among a
range of possible options, is likely to be the best option for a particular patient.

The Digital Display Precision Predictor (DDPP), is a biomarker strategy and tool able to predict the duration of progression-free survival (PFS) for multiple targeted treatments for patients with advanced/metastatic cancers, based on the comprehensive investigation of the whole
transcriptome (the gene expression profile of the tumor compared to that of normal tissue).
DDPP is based on: 1) the exploration of the whole transcriptome (20,000 genes) providing insight about the status of activation of almost all drug targets in the context of the network of genes or pathways that drive tumor progression; 2) the data can be obtained from a single assessment requiring very small amounts of tumor and analogous normal tissues; and 3) the prediction of the duration of the time until tumor progression (PFS) under a specific therapeutic regimen.

"One of the main challenges of finding new biomarkers is that they are built in a relatively small number of patients treated with the same drug (from the WINTHER trial), for whom both molecular profiles (from tumor and analogous normal tissues) and PFS data were available," said Dr. Josep Tabernero, Vice-Chairman and Chairman of Scientific Advisory Board of WIN, Director, Vall d'Hebron Institute of Oncology, VHIO (Spain) and past ESMO President (2018-2019).

"The DDPP is potentially a new global biomarker tool that can apply to any type of cancer drug used alone or in combination, agnostic of tumor type, and can lead, pending further prospective validation, to a new approach to optimal treatment selection for patients with cancer," concluded Dr. Richard L. Schilsky, Chairman of WIN.

Download the press release: Download pdf

© 1995-2021 IPD Group, Inc. All Rights Reserved